Drugs / D3L-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05957536 | Sep 2023 → Dec 2028 expected | — | D3 Bio (Wuxi) Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-31 | D3 Bio (Wuxi) Co., Ltd | Regulatory D3 Bio Announces Receiving an Orphan Drug Designation and Two IND Clearances from FDA for Its Compounds and Presentation of Pipeline Data at Upcoming AACR 2023 d3bio.com ↗
The Company received FDA’s IND clearance for D3L-001, a novel bispecific antibody targeting HER2 and CD47. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-31 | D3 Bio (Wuxi) Co., Ltd | D3 Bio Announces Receiving an Orphan Drug Designation and Two IND Clearances from FDA for Its Compounds and Presentation of Pipeline Data at Upcoming AACR 2023 d3bio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D3L-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05957536 ↗ |
| Route | Intravenous | “Intravenous administration” NCT05957536 ↗ |